$0.86
−1.22%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.91
From 52W high−85.41%
Volume321302.00
Market cap$87.52M
P/E (TTM)—
P/S (TTM)3.5x
Div yield—
Key dataNov 4, 2026
Open
$0.91
From 52W high
−85.41%
Volume
321302.00
Market cap
$87.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
32.1
MomentumView details →
1D Return
−1.22%
YTD Return
−80.64%
SummaryUpdated Jun 1, 2026
Nyxoah S.A. (NASDAQ:NYXH) is a Belgian medical technology company founded in 2009 and headquartered in Mont-Saint-Guibert, Belgium. The company went public on NASDAQ in April 2021, focusing on developing innovative solutions for sleep-disordered breathing conditions. Nyxoah has established itself as a challenger in the hypoglossal nerve stimulation market, primarily competing against established players like Inspire Medical Systems. The company has achieved commercial success in Europe, particularly Germany, and is preparing for its U.S. market launch following anticipated FDA approval in early 2025.
Similar companies
Latest newsMore news →
Nyxoah announced that it will release its third-quarter 2026 financial results on November 5, 2026.9d agoNyxoah reported preliminary unaudited third-quarter 2026 global net revenue of approximately €9.2 million, up 19% sequentially, and U.S. net revenue of approximately €6.7 million, up 29% sequentially.17d agoNyxoah submitted a PMA supplement to the FDA to expand Genio's U.S. indication to patients with Complete Concentric Collapse.17d ago